Ibogaine: A Clinical Summary
Clinical protocols Review low
AI-extracted · unverified · confirm at source
Industry marketing document, contradicts Alper 2012 on deaths, safety claims vs evidence mismatch.
Dosing: not-specified (oral)
Contraindications: Certain cardiovascular conditions (unspecified — refers to clinical guidelines), Coincident withdrawal from alcohol or benzodiazepines, Substances metabolised by CYP450-2D6 (including grapefruit and quinine)